Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Baricitinib, an oral Janus kinase (JAK) 1-2 inhibitor, is currently used along biologic DMARDs (bDMARDs) after the failure of methotrexate (MTX) in rheumatoid arthritis (RA). We investigated the efficacy and safety of baricitinib in real life.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Exp Rheumatol

Title: Clinical and experimental rheumatology

Publisher:

ISSN: 0392-856X

ISSN (Print): 0392-856X

Publication date (Electronic): December 19 2020

Volume: 39

Issue: 4

Affiliations

[1 ] Rheumatology and Clinical Immunology, Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy.

[2 ] Rheumatology, Azienda Ospedaliera Universitaria Integrata, Verona, University of Verona, Italy.

[3 ] Rheumatology, IRCCS San Raffaele Scientific Institute, Milan and Vita-Salute San Raffaele University, milan, Italy.

[4 ] Rheumatology, Azienda Sanitaria Universitaria Integrata and University of Udine, Italy.

[5 ] Internal Medicine, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.

[6 ] Rheumatology, Policlinico Le Scotte, University of Siena, Italy.

[7 ] Rheumatology, Allergy and Clinical Immunology, Department of Medicina dei Sistemi, University of Rome Tor Vergata, Italy.

[8 ] Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy.

[9 ] Rheumatology, ASST Papa Giovanni XXIII, Bergamo, Italy.

[10 ] Rheumatology, San Gerardo Hospital, Monza, Italy.

[11 ] Division of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, and Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Milan, Italy.

[12 ] Rheumatology, ASL3 Genovese, Genova, Italy.

[13 ] Division of Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, and Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Milan, Italy. carlo.selmi@humanitas.it.

Article

Publisher Item ID: 15729

DOI: 10.55563/clinexprheumatol/pudtpo

PubMed ID: 33338001

SO-VID: 86081632-11e1-4097-ab7c-d539dbcfc3f9

History

Data availability:

Comments

Comment on this article

scite_

Cited by 14

See all cited by